Another potential catalyst could be the breakup of the company, which management has said it will decide on by the end of this year. Under the plan, Pfizer would split into one firm developing new drugs and another focused on Pfizer's older treatments, as well as generics and biosimilars, which resemble generics but have more complex molecular structures.